The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...

Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...

Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for the same period in 2023. The increase of $10.2 million was primarily driven ...

Celltrion, a major South Korean biopharmaceutical firm, on Thursday said it has launched its biosimilar product for Stelara, a ...

The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for ...

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in ...

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent ... significantly reducing the disease burden on nasal polyp patients. Many nasal polyp patients face the risk of ...

Celltrion, a major South Korean biopharmaceutical firm, said on Monday that its biosimilar for asthma and other chronic allerg ...

The U.S. Food and Drug Administration (FDA) approved Celltrion's Omlyclo, a biosimilar drug to Xolair, for treatment of moderate to severe persistent asthma, chronic rhinosinusitis with nasal polyps ...

CRSwNP is an inflammatory condition which results ... shown efficacy in a phase 3 trial in chronic obstructive pulmonary disease (COPD). It is one of GSK's top drugs, with sales of $2.2 billion ...